Together, these findings suggested that miR-146a limits IL-17-promoting cytokines in myeloid cells by targeting RIPK2, thereby inhibiting myeloid-driven IL-17 producers in the colonic microenvironment and reducing CRC development. Here, RIPK2 is linked to colorectal carcinoma.